Media headlines about Amedisys (NASDAQ:AMED) have trended somewhat positive on Thursday, Accern reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Amedisys earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave press coverage about the health services provider an impact score of 45.8619438061544 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the news stories that may have effected Accern Sentiment Analysis’s scoring:

Shares of Amedisys (AMED) remained flat at $53.50 on Thursday. 98,839 shares of the company’s stock were exchanged. Amedisys has a 52 week low of $34.58 and a 52 week high of $65.91. The company’s 50 day moving average price is $51.90 and its 200 day moving average price is $55.18. The stock has a market capitalization of $1.81 billion, a PE ratio of 45.73 and a beta of 0.87.

Amedisys (NASDAQ:AMED) last posted its earnings results on Wednesday, July 26th. The health services provider reported $0.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.50 by $0.12. Amedisys had a return on equity of 13.71% and a net margin of 2.70%. The company had revenue of $378.80 million for the quarter, compared to analyst estimates of $380.80 million. During the same quarter in the previous year, the firm earned $0.42 earnings per share. The firm’s quarterly revenue was up 5.0% compared to the same quarter last year. Equities research analysts predict that Amedisys will post $2.21 EPS for the current fiscal year.

A number of brokerages have recently weighed in on AMED. Mizuho lowered shares of Amedisys from a “buy” rating to a “neutral” rating and set a $50.00 price objective for the company. in a report on Wednesday, July 26th. Robert W. Baird reiterated a “hold” rating and set a $50.00 price target on shares of Amedisys in a report on Wednesday. Bank of America Corporation assumed coverage on shares of Amedisys in a report on Monday, August 21st. They set a “neutral” rating and a $55.00 price target for the company. BidaskClub upgraded shares of Amedisys from a “sell” rating to a “hold” rating in a report on Friday, August 11th. Finally, Oppenheimer Holdings, Inc. reiterated a “buy” rating and set a $60.00 price target on shares of Amedisys in a report on Friday, September 15th. Seven analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Amedisys currently has a consensus rating of “Hold” and a consensus price target of $55.44.

COPYRIGHT VIOLATION WARNING: This piece of content was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at

In related news, insider David B. Pearce sold 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $50.00, for a total value of $50,000.00. Following the sale, the insider now owns 10,488 shares in the company, valued at $524,400. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Bruce D. Perkins bought 2,000 shares of the company’s stock in a transaction that occurred on Thursday, August 3rd. The stock was purchased at an average price of $46.60 per share, for a total transaction of $93,200.00. Following the transaction, the director now owns 15,825 shares of the company’s stock, valued at $737,445. The disclosure for this purchase can be found here. 2.00% of the stock is currently owned by insiders.

Amedisys Company Profile

Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.

Insider Buying and Selling by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Stock Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related stocks with our FREE daily email newsletter.